

Lead candidate selected in ExpreS²ion's HER2-cVLP breast cancer vaccine project

Hørsholm, Denmark, May 11, 2021 – ExpreS²ion Biotech Holding AB's affiliate ExpreS²ion Biotechnologies ApS ("ExpreS²ion") announces the selection of its lead candidate HER2-cVLP breast cancer vaccine. The project runs according to plan.

ExpreS²ion, with the expert assistance of Prof. Pier Luigi Lollini at the Interdepartmental Center for Cancer Research, University of Bologna, has started the preclinical program, exploiting state-of-the-art *in vitro* and *in vivo* models mimicking some of the mechanisms in human breast cancer.

As part of the preclinical program, ExpreS²ion has selected the lead candidate, ES2B-C001, from a pool of several optimized constructs. The lead candidate - even without adjuvant - has been found to induce high anti-HER2 antibody titres when compared to a former construct earlier published in [Oncolimmunology, 2018](#).

The ES2B-C001 breast cancer vaccine programme continues to be on path towards expected preclinical proof of concept data at the end of 2021, as well as starting the clinical program in 2022 with GMP manufacturing of ES2B-C001 with the plan to start a clinical Phase I safety and immune response study in beginning of 2023.

CEO Bent U. Frandsen comments

"Following the recent in-licensing of the HER2-cVLP breast cancer vaccine project from AdaptVac, as well as the initiation of the preclinical work in collaboration with Prof. Lollini at University of Bologna, it now becomes very tangible following the selection of the lead vaccine candidate. I am pleased that we are on track on this exciting project."

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se

For further information about ExpreS²ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com

This press release constitutes inside information that ExpreS²ion Biotech Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company's news distributor, Cision, at the publication of this press release.

About ExpreS²ion

ExpreS²ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS²ion Biotech Holding AB with company register number 559033-3729. ExpreS²ion has developed a unique technology platform, ExpreS², for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS² is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS²ion develops novel VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.